EV Biologics is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.

Motivated by the desire to improve health and longevity, our scientists, physicians, and executive leadership have boldly ventured to advance the science and medicine of extracellular vesicles. EV Biologics is working to bring exosome diagnostic and therapeutic technology into future clinical practice.

“The reality is that our technology is far superior to anything currently on the market. We will be far better off focusing on the development of our own innovative products in our lab. We will do so through the optimization of EVs produced by a series of natural and bioengineered cell lines designed to enhance the remarkable intrinsic biological properties of mesenchymal stem cells (MSCs) and other progenitor cells.”

Dr. Jason SandersChief Medical Officer

Disease-specific EVs produced by these types of optimized cell lines will be developed into biological drugs seeking FDA approval for several different clinical indications: acute lung injury (eg. COVID-19, influenza, acute respiratory distress syndrome), autoimmune (lupus, multiple sclerosis, rheumatoid arthritis, etc) and systemic inflammatory syndromes, osteoarthritis and other degenerative musculoskeletal diseases, neurodegenerative conditions, metabolic diseases, and other age-related conditions.

Press Releases